CCM
BLPH

CAAS Capital Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

CAAS Capital Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-97,900
Closed -$508K – 1509
2021
Q1 		$508K Buy
+97,900
New +$682K 0.01% 914

Other funds holding BLPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CAAS Capital Management's BLPH Position: Q2 2021 in Review

CAAS Capital Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2021, closing a stake of 97,900 shares — an estimated $508K sold.

CAAS Capital Management first reported a position in BLPH in Q1 2021 and held it in 1 quarter. The position peaked at $508K in Q1 2021. 27 funds tracked by Wall St. Rank hold BLPH as of Q2 2021.

  • CAAS Capital Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 97,900 Bellerophon Therapeutics, Inc. shares in Q2 2021, an estimated $508K.
  • CAAS Capital Management first reported a position in Bellerophon Therapeutics, Inc. in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's Bellerophon Therapeutics, Inc. position peaked at $508K in Q1 2021.
  • 27 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.